Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations drive colorectal cancer development, with missense mutations frequently leading to accumulation of abnormal TP53 protein.
|
31471586 |
2020 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that cepharanthine is a promising agent for treating patients with colorectal cancer containing p53 mutation.
|
30693808 |
2020 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The circ_0021977/miR-10b-5p/P21 and P53 regulatory axis suppresses proliferation, migration, and invasion in colorectal cancer.
|
31595500 |
2020 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using drug-resistant TP53-null colon cancer cells as a model we demonstrated that p65BTK silencing or chemical inhibition overcame the 5-fluorouracil resistance of CRC cell lines and patient-derived organoids and significantly reduced the growth of xenografted tumours.
|
31518438 |
2020 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Finally, lnc273-31 and lnc273-34 were significantly highly expressed in CRC tissues with p53-R273H mutation compared to those with wildtype p53.
|
31455383 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs.
|
29860032 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeted sequencing panel analysis for MSU CRCs showed that B2M-mutated MSU CRCs harbored more driver mutations including TP53 than B2M-wild-type MSU CRCs.
|
30503610 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this review, we comprehensively summarize the GOF of p53 mutants in CRC progression as well as in some other solid tumors, and discuss the current strategies targeting p53 mutants in malignancies.
|
31795192 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
APC and TP53 mutations were less frequent in MC compared to those in TCGA-CON (p < 0.001 and 0.003, respectively) whereas KRAS mutation was prevalent (p = 0.041).
|
31400926 |
2019 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Here, we determined CC3, p-MLKL, and LC3B expression in colorectal cancers (CRCs), and assessed their associations with clinicopathological parameters, and with KRAS and p53 status.
|
31097354 |
2019 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to analyze the cytostatic/cytotoxic response of colorectal carcinoma (CRC) cells to irinotecan, depending on the mismatch repair (MMR) and p53 status and to examine the impact of BV6, a bivalent antagonist of inhibitors of apoptosis c-IAP1/c-IAP2, alone or combined with irinotecan.
|
31289894 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Butyrate differentiates HT-29 cells by relaxing the perturbation, caused by mutations of Adenomatous polyposis coli (APC) and TP53 genes, the most frequent mutations observed in CRC.
|
30475060 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the impact and potential mechanisms of p53 polymorphisms on human malignancies have been intensively studied, analyses for association between p53 polymorphisms and colorectal cancer (CRC) risk were still limited to some common variants.
|
31205533 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We compared the phenotypic effects of the common human cancer-associated TP53 R273H missense mutation to p53 null status in a genetically engineered mouse CRC model.
|
31148594 |
2019 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We analysed CRCs (N = 621) for the presence of TP53 alterations and for p53 expression, using targeted resequencing and immunohistochemistry.
|
30894685 |
2019 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
<i>TP53, KRAS, APC</i>) has limited diagnostic sensitivity (40-60%), however, methylated DNA including <i>SEPT9, SFRP1, SDC2</i> can be applied with higher sensitivity (up to 90%) for CRC.Circulating miRNAs (e.g. miR-21, miR-92, miR-141) provide comparably high sensitivity for CRC as the circulating tumor cell mRNA markers (e.g.EGFR, CK19, CK20, CEA).
|
31046485 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Detailed morphological evaluation, immunohistochemical analysis of mismatch repair (MMR) proteins, p53 and O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) expression and molecular analysis for KRAS, NRAS and BRAF gene mutation were performed in the retrieved CRC cases as well as in the detected dysplasia and PPLs of these patients.
|
30679085 |
2019 |
Colorectal Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, flavopereirine enhanced P53 expression and phosphorylation in CRC cells.
|
31336690 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We therefore investigated the anti-tumor properties of a gold(I) <i>N</i>-heterocyclic carbene (NHC) complex-termed MC3-in human colorectal cancer (CRC) cell lines encompassing three different p53 variations: HCT116 wild-type (WT), HCT116 p53<sup>-/-</sup>, and HT-29 (mutant; R273H).
|
31231607 |
2019 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this review, we have set the spotlight on role of JAK/STAT, TGF/SMAD, Notch, WNT/β-Catenin, SHH/GLI and p53 pathways in the development and progression of colorectal cancer.
|
30633978 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in TP53 were most common and were present in 69% of IBD-CRCs; a similar percentage of TP53 mutations was detected in sporadic colorectal carcinomas (70%).
|
31054900 |
2019 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Accordingly, the suppression of the mutant p53 function via the inhibition of nuclear accumulation is expected to be an effective strategy against malignant progression of colorectal cancer.
|
30496442 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
On the contrast, all genetic models showed no statistical association of TP53 Pro47Ser polymorphism among CRC patients compared with healthy controls.
|
29560751 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Twenty percent CIN + CRCs harboured mutations only in TP53 - a profile not seen in the MACS tumours (p = 0.009).
|
31153694 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic TP53 mutations occurred in 33% of ulcerative colitis-associated CRCs.
|
30794281 |
2019 |